CCR5 antagonist: Promising agents in HIV treatment

HIV enters the bloodstream via binding to receptors on the surface of host cells. The CD4+ cell is a kind of white blood cell. Viral access to It all starts with the CD4+ cell. R5 HIV-1 Virus Attachment gp120 (glycoprotein 120) to The CD4+ T-cell receptor (CD4+ TCR) is a type of T-cell receptor that gives rise to a conformational a modification in gp120 that enables it to connect to CCR5, causing it to activate gp41 (glycoprotein 41) mediates the viral envelope is fused with membrane of the cell and the nucleocapsid makes its way into the host a cell. CCR5 is a kind of co-receptor by inhibiting CCR5 cell surface, antagonists prevent HIV-1 from entering and infecting immune cells receptor. CCR5 antagonists are small molecules that attach to a hydrophobic pocket produced by CCR5. The CCR5 receptor's trans membrane helices They're thought to interact with the receptor in the brain. The review gives a brief description of currently used CCR5 antagonists.